The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis

MA de Sauvage, C Torrini, E Nieblas-Bedolla… - Neuro …, 2024 - academic.oup.com
Background Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment;
however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating …
被引用次数：1 相关文章

The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.

MA de Sauvage, C Torrini, E Nieblas-Bedolla… - Neuro …, 2023 - europepmc.org
Background Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment;
however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating …

The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis

MA de Sauvage, C Torrini, E Nieblas-Bedolla… - Neuro …, 2024 - academic.oup.com
Background Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment;
however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating …

The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis

MA de Sauvage, C Torrini… - Neuro …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment;
however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating …